An academic hospital experience screening mRNA COVID-19 vaccine risk using patient allergy history

Abstract

Higher than expected rates of anaphylaxis have been reported with the Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines when compared with historical vaccine anaphylaxis trends.1 Although the mechanism for such reactions remains unclear, and current anaphylaxis classification schemes may be overly sensitive, early interest has been placed on polyethylene glycol (PEG) 2000 present in the lipid nanoparticle carrier system of these mRNA COVID-19 vaccines.2 In order to attempt to preempt allergic reactions, use of mRNA COVID-19 vaccines has been contraindicated in patients with known allergy to PEG and previously contraindicated in those with known allergy to PEG derivatives such as polysorbate where small studies have suggested cross-reactivity with PEG.